Abstract:
Release Date: November 16, 2009
Expiration Date: September 30, 2010
Time to complete activity:
Case #1 Platinum Resistant - 4 months 18 minutes
Case #2 Biochemical Recurrence - 10 months 14 minutes
Case #2 Platinum Sensitive - 20 months 14 minutes
Sponsors:
This activity is jointly sponsored by the Univeristy of Michigan Medical School and IMPACt, Inc.
Commercial Support:
This activity is supported by an educational grant from Genentech.
Description:
”Virtual Ovarian Tumor Board: Recurrent Cases” is a case-based discussion that focuses on current issues and changing dynamics in the treatment of patients with recurrent ovarian cancer. Issues to be explored by this activity include:
- How to select the optimal therapy based on efficacy vs. toxicity profile/quality of life
- Use of non-platinum doublets for platinum-sensitive disease
- What is the potential role of targeted therapy?
- Is there a role for cytoreductive surgery or radiation therapy in recurrent disease?
- Should CA-125 levels alone determine when to initiate treatment in recurrent ovarian cancer?
- How do you treat a patient who has received multiple regimens and still wishes to continue treatment?
Learning Objectives:
Case 1: Platinum-resistant disease (recurrence at 4 months)
- Outline treatment goals for the recurrent ovarian cancer case presented
- Discuss evidence-based therapy recommendations for the recurrent ovarian cancer case presented
- Describe the results of recent clinical trials evaluating chemotherapy regimens for recurrent ovarian cancer
- Discuss the research into the use of novel agents in patients with recurrent ovarian cancer
Case 2: Recurrent disease at 10 months
- Discuss evidence-based therapy recommendations for the recurrent ovarian cancer case presented
- Describe the results of recent clinical trials evaluating chemotherapy regimens for recurrent ovarian cancer
- Discuss research into whether CA-125 levels alone determine when to initiate treatment in recurrent ovarian cancer
Case 3: Recurrent disease at 20 months
- Outline treatment goals for the recurrent ovarian cancer case presented
- Discuss evidence-based therapy recommendations for the recurrent ovarian cancer case presented
- Discuss the research into the use of novel agents in patients with recurrent ovarian cancer
- Describe the role of secondary cytoreduction for patients with recurrent ovarian cancer
Target Audience:
This activity has been designed to meet the educational needs of medical oncologists and gynecologic oncologists involved in the care of patients with ovarian cancer.
Accreditation Statement:
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the University of Michigan Medical School and IMPACt, Inc. The University of Michigan Medical School is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
The University of Michigan Medical School designates each of these case presentations for a maximum of .25 AMA PRA Category 1 credits. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Agenda:
Introduction
Case 1: Platinum-Resistant – 4 months
Best therapeutic approach
- Chemotherapeutics
- Novel agents (cytotoxics/biologics)
- Symptom management
Clinical trials
Expectations of Therapy
Case 2: Biochemical Recurrence – 10 months
Rationale for biomarker surveillance
- Intervention for biomarker/symptom changes
- Imaging techniques
Institution of therapy
- When
- Single agent vs Combination
- Platinum-based vs. non-platinum-based
- Surgery
- Expectations of therapy
Clinical studies
Case 3: Platinum-Sensitive – 20 months
Surgical candidacy
- Imaging
- Disease chemosensitivity
- Goals of surgery
Faculty:
Robert Coleman, MD (Course Director)
Professor and Director of Clinical Research
Department of Gynecologic Oncology
The University of Texas M. D. Anderson Cancer Center
Bradley J Monk, MD FACOG FACS
Associate Professor and Director of Research
Division of Gynecologic Oncology
Department of Obstetrics and Gynecology
Chao Family Comprehensive Cancer Center
University of California Irvine Medical Center
Thomas J. Herzog, MD
Physicians & Surgeons Alumni Professor of Clinical Obstetrics and Gynecology
Director, Division of Gynecologic Oncology
The Herbert Irving Comprehensive Cancer Center
Columbia University College of Physicians & Surgeons
University of Michigan CME Content Reviewer
Samuel M. Silver, MD, PhD
Professor and Associate Dean for Research
University of Michigan Medical School
Director, University of Michigan
Cancer Center Network
University of Michigan Healthcare Network
Disclosure of Conflicts of Interest:
The University of Michigan Medical School endorses the Standards of the Accreditation Council for Continuing Medical Education and the Guidelines of the Association of American Medical Colleges that the sponsors of continuing medical education activities and the speakers at these activities disclose significant relationships with commercial companies whose products are discussed in educational presentations. Disclosure of a relationship is not intended to suggest or condone bias in any presentation, but is made to provide participants with information that might be of potential importance to their evaluation of a presentation.
Significant relationships exist with the following companies whose products will be discussed.
Robert Coleman, MD
Consultant: Centocor, Genentech, GlaxoSmithKline and Morphotek
Speaker’s Bureau: Eli Lilly and Centocor
Grant/Research: Genentech, Novartis and sanofi-aventis
Thomas J. Herzog, MD
Consultant: Genentech, GlaxoSmithKline, Ortho Biotech/Johnson & Johnson
Speaker’s Bureau: Amgen, Cytyc, GlaxoSmithKline, Eli Lilly, Merck
and Ortho Biotech/ J&J
Grant/Research: Genentech
Bradley J. Monk, MD, FACOG, FACS
Speaker’s Bureau: Eli Lilly
Grant/Research: GlaxoSmithKline, Johnson & Johnson and sanofi-aventis
Samuel M. Silver, MD, PhD
Consultant: Blue Cross Blue Shield of Michigan
Grant/Research Blue Cross Blue Shield of Michigan